Solyphar plans to build a drug manufacturing plant in Uzbekistan
Egypt based pharmaceutical trading company- Solyphar plans to develop a drug manufacturing
plant in Uzbekistan. The company is primarily engaged in supply of drugs to the Commonwealth
of Independent States (CIS), Latin America, and Southern Africa countries.
The company plans to develop the manufacturing unit in Tashkent, Uzbekistan. The
pharmaceutical plant is estimated to cost around $20 million. It will have a planned manufacturing
capacity of 500 million tablets, 200 million capsules, and 10 million sachets.
Strong demand for pharmaceuticals, dietary supplements and veterinary products in the CIS region
will provide strong opportunities for the company. In particular, with significant unmet demand in
Uzbekistan and other Eastern European countries, the new plant will enable the company to tap
the segment.